Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action

NCT01945047 is registered in ClinicalTrials.gov with University of Ottawa as lead sponsor.

NCT NCT01945047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01945047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action
Lead sponsor
University of Ottawa
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2013
Completion date
December 31, 2017
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment-resistant depression